OncoCyte Analyst Ratings
OncoCyte Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/13/2023 | 8.79% | Piper Sandler | $3.5 → $3 | Maintains | Neutral |
11/09/2023 | 30.55% | Needham | $4.25 → $3.6 | Maintains | Buy |
08/24/2023 | 81.32% | Benchmark | $9 → $5 | Maintains | Speculative Buy |
08/15/2023 | 26.93% | Piper Sandler | $6 → $3.5 | Maintains | Neutral |
08/10/2023 | 54.13% | Needham | $9 → $4.25 | Maintains | Buy |
04/04/2023 | -83.68% | Needham | $1.4 → $0.45 | Maintains | Buy |
12/01/2022 | -81.87% | Lake Street | $3 → $0.5 | Downgrades | Buy → Hold |
11/18/2022 | -81.87% | Piper Sandler | $1 → $0.5 | Downgrades | Overweight → Neutral |
11/14/2022 | -63.74% | Piper Sandler | $1.5 → $1 | Maintains | Overweight |
11/11/2022 | -49.23% | Needham | $2.1 → $1.4 | Maintains | Buy |
08/17/2022 | -45.6% | Piper Sandler | $1.4 → $1.5 | Maintains | Overweight |
08/11/2022 | 8.79% | Lake Street | $6 → $3 | Maintains | Buy |
08/11/2022 | -23.84% | Needham | $2.25 → $2.1 | Maintains | Buy |
05/24/2022 | — | Stephens & Co. | Downgrades | Overweight → Equal-Weight | |
05/16/2022 | -49.23% | Piper Sandler | $1.8 → $1.4 | Maintains | Overweight |
05/12/2022 | -18.4% | Needham | $4 → $2.25 | Maintains | Buy |
03/18/2022 | -34.72% | Piper Sandler | $3.1 → $1.8 | Maintains | Overweight |
03/14/2022 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
03/11/2022 | 117.59% | Lake Street | $11 → $6 | Maintains | Buy |
03/11/2022 | 45.06% | Needham | $5 → $4 | Maintains | Buy |
01/07/2022 | 12.42% | Stephens & Co. | → $3.1 | Initiates Coverage On | → Overweight |
12/16/2021 | 81.32% | Needham | $7 → $5 | Maintains | Buy |
11/10/2021 | 153.85% | Needham | $8 → $7 | Maintains | Buy |
03/17/2021 | 190.12% | Needham | → $8 | Assumes | → Buy |
12/16/2020 | 45.06% | Piper Sandler | $2 → $4 | Upgrades | Neutral → Overweight |
11/30/2020 | 81.32% | BTIG | → $5 | Initiates Coverage On | → Buy |
11/13/2020 | 45.06% | Needham | $2 → $4 | Maintains | Buy |
11/10/2020 | 81.32% | Keybanc | → $5 | Initiates Coverage On | → Overweight |
07/30/2020 | 117.59% | Benchmark | $7 → $6 | Maintains | Speculative Buy |
07/01/2020 | -27.47% | Needham | $4 → $2 | Maintains | Buy |
06/30/2020 | -27.47% | Chardan Capital | $7.75 → $2 | Downgrades | Buy → Neutral |
06/02/2020 | 45.06% | Needham | → $4 | Initiates Coverage On | → Buy |
02/13/2019 | 117.59% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析師公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/13/2023 | 8.79% | 派珀·桑德勒 | 3.5 美元 → 3 美元 | 維護 | 中立 |
11/09/2023 | 30.55% | 尼德姆 | 4.25 美元 → 3.6 美元 | 維護 | 買 |
08/24/2023 | 81.32% | 基準 | 9 美元 → 5 美元 | 維護 | 投機性買入 |
08/15/2023 | 26.93% | 派珀·桑德勒 | 6 美元 → 3.5 美元 | 維護 | 中立 |
08/10/2023 | 54.13% | 尼德姆 | 9 美元 → 4.25 美元 | 維護 | 買 |
04/04/2023 | -83.68% | 尼德姆 | 1.4 美元 → 0.45 美元 | 維護 | 買 |
2022 年 1 月 12 日 | -81.87% | 湖街 | 3 美元 → 0.5 美元 | 降級 | 買入 → 持有 |
11/18/2022 | -81.87% | 派珀·桑德勒 | $1 → 0.5 美元 | 降級 | 超重 → 中立 |
11/14/2022 | -63.74% | 派珀·桑德勒 | 1.5 美元 → 1 美元 | 維護 | 超重 |
11/11/2022 | -49.23% | 尼德姆 | 2.1 美元 → 1.4 美元 | 維護 | 買 |
08/17/2022 | -45.6% | 派珀·桑德勒 | 1.4 美元 → 1.5 美元 | 維護 | 超重 |
08/11/2022 | 8.79% | 湖街 | 6 美元 → 3 美元 | 維護 | 買 |
08/11/2022 | -23.84% | 尼德姆 | 2.25 美元 → 2.1 美元 | 維護 | 買 |
2022 年 5 月 24 日 | — | Stephens & Co. | 降級 | 超重 → 重量相等 | |
05/16/2022 | -49.23% | 派珀·桑德勒 | 1.8 美元 → 1.4 美元 | 維護 | 超重 |
05/12/2022 | -18.4% | 尼德姆 | 4 美元 → 2.25 美元 | 維護 | 買 |
03/18/2022 | -34.72% | 派珀·桑德勒 | 3.1 美元 → 1.8 美元 | 維護 | 超重 |
03/14/2022 | — | Keybanc | 降級 | 增持 → 板塊權重 | |
03/11/2022 | 117.59% | 湖街 | 11 美元 → 6 美元 | 維護 | 買 |
03/11/2022 | 45.06% | 尼德姆 | 5 美元 → 4 美元 | 維護 | 買 |
2022 年 7 月 1 日 | 12.42% | Stephens & Co. | → 3.1 美元 | 啓動覆蓋範圍開啓 | → 超重 |
2021 年 12 月 16 日 | 81.32% | 尼德姆 | 7 美元 → 5 美元 | 維護 | 買 |
11/10/2021 | 153.85% | 尼德姆 | 8 美元 → 7 美元 | 維護 | 買 |
03/17/2021 | 190.12% | 尼德姆 | → 8 美元 | 假設 | → 購買 |
2020 年 12 月 16 日 | 45.06% | 派珀·桑德勒 | 2 美元 → 4 美元 | 升級 | 中立 → 超重 |
11/30/2020 | 81.32% | BTIG | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
11/13/2020 | 45.06% | 尼德姆 | 2 美元 → 4 美元 | 維護 | 買 |
11/10/2020 | 81.32% | Keybanc | → 5 美元 | 啓動覆蓋範圍開啓 | → 超重 |
07/30/2020 | 117.59% | 基準 | 7 美元 → 6 美元 | 維護 | 投機性買入 |
07/01/2020 | -27.47% | 尼德姆 | 4 美元 → 2 美元 | 維護 | 買 |
06/30/2020 | -27.47% | 查丹資本 | 7.75 美元 → 2 美元 | 降級 | 買入 → 中性 |
06/02/2020 | 45.06% | 尼德姆 | → 4 美元 | 啓動覆蓋範圍開啓 | → 購買 |
02/13/2019 | 117.59% | 派珀·桑德勒 | → 6 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for OncoCyte (OCX)?
OncoCyte(OCX)的目標價格是多少?
The latest price target for OncoCyte (NASDAQ: OCX) was reported by Piper Sandler on November 13, 2023. The analyst firm set a price target for $3.00 expecting OCX to rise to within 12 months (a possible 8.79% upside). 9 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年11月13日公佈了OncoCyte(納斯達克股票代碼:OCX)的最新目標股價。該分析公司將目標股價定爲3.00美元,預計OCX將在12個月內上漲至3.00美元(可能上漲8.79%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for OncoCyte (OCX)?
分析師對OncoCyte(OCX)的最新評級是多少?
The latest analyst rating for OncoCyte (NASDAQ: OCX) was provided by Piper Sandler, and OncoCyte maintained their neutral rating.
OncoCyte(納斯達克股票代碼:OCX)的最新分析師評級由派珀·桑德勒提供,OncoCyte維持中性評級。
When is the next analyst rating going to be posted or updated for OncoCyte (OCX)?
OncoCyte(OCX)的下一個分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OncoCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OncoCyte was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與OncoCyte的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應獲得4個評級。OncoCyte的最後一次評級是在2023年11月13日提交的,因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating OncoCyte (OCX) correct?
分析師對OncoCyte(OCX)的評級是否正確?
While ratings are subjective and will change, the latest OncoCyte (OCX) rating was a maintained with a price target of $3.50 to $3.00. The current price OncoCyte (OCX) is trading at is $2.76, which is out of the analyst's predicted range.
儘管評級是主觀的,並將發生變化,但最新的OncoCyte(OCX)評級維持不變,目標股價爲3.50美元至3.00美元。OncoCyte(OCX)目前的交易價格爲2.76美元,超出了分析師的預測區間。